Republicans Scrutinize FDA's Vouchers, Generic Drug Approvals
- Lawmakers cite Shkreli's KaloBios purchase in voucher review
- FDA asked to explain what it's doing to protect vouchers
This article is for subscribers only.
House Republicans are seeking information about priority vouchers awarded to makers of drugs for rare diseases, asking whether the Food and Drug Administration program is being taken advantage of.
House Oversight Committee Chairman Jason Chaffetz and 12 committee members wrote a letter to Acting FDA Commissioner Stephen Ostroff on Tuesday seeking the documents and data as part of an investigation into recent price hikes on older drugs. The lawmakers are also seeking information on the FDA’s process for reviewing generic drug applications.